Results 11 to 20 of about 19,757 (182)
Portopulmonary hypertension practice patterns after liver transplantation
Liver Transplantation, EarlyView., 2022 Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose +3 more
wiley +1 more source
Oral bioavailability and pharmacokinetics of sildenafil citrate dry foam tablets in rats
Cogent Medicine, 2018 Sildenafil has low water solubility and oral bioavailability. Dry foam formulations of solid dosage forms of poorly water-soluble drugs may exhibit improved dissolution and bioavailability.
Somchai Sawatdee +7 more
doaj +1 more source
Journal of Medical Case Reports, 2023 Background Sildenafil is a selective phosphodiesterase type 5 inhibitor used for the treatment of erectile dysfunction and pulmonary hypertension. It is available over the counter in many countries. While there have been a few reports of retinal vascular
Ali Torkashvand +3 more
doaj +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
N‐Alkoxysulfurdiimide Reagents for the One‐Step Modular Synthesis of Primary Sulfonimidamides
Angewandte Chemie, EarlyView.N‐Alkoxysulfurdiimide reagents when combined with organometallic reagents lead directly to primary sulfonimidamide products. The reactions are broad in scope, encompassing aryl, heteroaryl, and alkyl carbon substituents. The reactivity of the N‐alkoxysulfurdiimide reagents can be correlated with the electron‐withdrawing ability of the N‐substituent ...
Suzanne E. Davison +6 more
wiley +2 more sources
EBioMedicine, 2019 Background: The phosphodiesterase-5 inhibitor (PDE5) sildenafil has emerged as a promising treatment for preeclampsia (PE). However, a sildenafil trial was recently halted due to lack of effect and increased neonatal morbidity.
Emilie Hitzerd +11 more
doaj +1 more source
Appropriateness of Sildenafil Prescribing in Pulmonary Hypertension with Valvular Heart Disease: A Single Centre Study [PDF]
Trends in Pharmaceutical Sciences, 2022 Oral sildenafil has proven efficacy in pulmonary hypertension in current clinical practice. However, there is a research gap in sildenafil prescribing among patients with valvular heart disease (VHD) and pulmonary hypertension (PH) in Malaysia.
Tze Hoon Goo +5 more
doaj +1 more source
Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review
BMJ Open Sport & Exercise Medicine, 2019 Objective Sildenafil is a pulmonary vasodilator that may reduce the decrement in endurance performance in moderate hypoxia. We assessed the efficacy of sildenafil to improve performance in hypoxia.Data sources/eligibility Criteria We systematically ...
Eric Alexander Carter +3 more
doaj +1 more source
Potential Protective Role of Nigella sativa Linn against Sildenafil Induced Hepatotoxicity and Nephrotoxicity in Adult Male Rabbits [PDF]
Ain Shams Journal of Forensic Medicine and Clinical Toxicology, 2018 Introduction: Nigella sativa is considered to have antioxidant components though it is proposed to have hepatoprotective and nephroprotective effect. Aim of the study: This study aimed to investigate hepatotoxic and nephrotoxic effects of sildenafil and ...
Elsayed Abouelnour +3 more
doaj +1 more source
Infectious Disease Reports, 2015 Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello +7 more
doaj +1 more source